Actively Recruiting

Phase 1
Age: 19Years +
All Genders
NCT05172310

PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI

Led by Karolinska University Hospital · Updated on 2021-12-29

410

Participants Needed

1

Research Sites

408 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Cancers of the pancreas, bile ducts, stomach and ovaries are dismal diseases with most patients being diagnosed in advanced stages leading to a bad prognosis. These cancers can be difficult to diagnose and sometimes impossible to differentiate from underlying benign conditions. Establishing the correct diagnosis of primary cancer lesions and possible spread to other organs in time is pivotal for choosing the right therapy. Routinely applied staging procedures are however not always reliable. The main aim in this study is to evaluate the diagnostic accuracy of PET/CT with a novel radiotracer, FAPI, in the primary diagnosis of cancers in the pancreas, stomach and bile ducts as well as in patients with primary and recurrent epithelial ovarian cancer (EOC).

CONDITIONS

Official Title

PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI

Who Can Participate

Age: 19Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

Inclusion Criteria:

  • Consecutive patients scheduled for surgical removal of either a pancreatic, biliary or gastric lesion.

    - Consecutive patients scheduled for primary surgical removal of early stage epithelial ovarian cancer (EOC), interval debulking surgery of EOC or surgical removal or tissue biopsy of recurrent EOC

  • Signed informed consent.

Common Exclusion Criteria for all study populations:

  • Age ≤18 year
  • Pregnancy and lactation
  • Significantly reduced renal function
  • Allergy to iodinated contrast media
  • Subjects that for some reason are unable to exercise their own rights, such as cognitive function impairment.

Additional Exclusion Criteria for study populations with either pancreatic-, gastric or bile duct cancer:

• Known metastatic disease

Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Karolinska University Hospital Huddinge

Stockholm, Sweden, 14186

Actively Recruiting

Loading map...

Research Team

R

Rimma Axelsson, Professor

CONTACT

S

Siri af Burén, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

DIAGNOSTIC

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here